ZIVO BIOSCIENCE INC (ZIVO) Fundamental Analysis & Valuation

NASDAQ:ZIVO • US98978N3098

Current stock price

1.1 USD
-0.05 (-4.35%)
At close:
1.12 USD
+0.02 (+1.82%)
After Hours:

This ZIVO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ZIVO Profitability Analysis

1.1 Basic Checks

  • ZIVO had negative earnings in the past year.
  • In the past year ZIVO has reported a negative cash flow from operations.
ZIVO Yearly Net Income VS EBIT VS OCF VS FCFZIVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M

1.2 Ratios

  • The Return On Assets of ZIVO (-404.76%) is worse than 94.87% of its industry peers.
Industry RankSector Rank
ROA -404.76%
ROE N/A
ROIC N/A
ROA(3y)-1550.36%
ROA(5y)-2266.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZIVO Yearly ROA, ROE, ROICZIVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 20K 40K 60K 80K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ZIVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZIVO Yearly Profit, Operating, Gross MarginsZIVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. ZIVO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ZIVO has about the same amount of shares outstanding.
  • ZIVO has a worse debt/assets ratio than last year.
ZIVO Yearly Shares OutstandingZIVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
ZIVO Yearly Total Debt VS Total AssetsZIVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

  • Based on the Altman-Z score of -94.02, we must say that ZIVO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -94.02, ZIVO is not doing good in the industry: 97.44% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -94.02
ROIC/WACCN/A
WACCN/A
ZIVO Yearly LT Debt VS Equity VS FCFZIVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

2.3 Liquidity

  • ZIVO has a Current Ratio of 0.62. This is a bad value and indicates that ZIVO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ZIVO has a Current ratio of 0.62. This is amonst the worse of the industry: ZIVO underperforms 84.62% of its industry peers.
  • ZIVO has a Quick Ratio of 0.62. This is a bad value and indicates that ZIVO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ZIVO (0.62) is worse than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.62
ZIVO Yearly Current Assets VS Current LiabilitesZIVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ZIVO Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.67% over the past year.
EPS 1Y (TTM)1.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZIVO Yearly Revenue VS EstimatesZIVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 200K 400K 600K 800K
ZIVO Yearly EPS VS EstimatesZIVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZIVO Valuation Analysis

4.1 Price/Earnings Ratio

  • ZIVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ZIVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZIVO Price Earnings VS Forward Price EarningsZIVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZIVO Per share dataZIVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZIVO Dividend Analysis

5.1 Amount

  • No dividends for ZIVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ZIVO Fundamentals: All Metrics, Ratios and Statistics

ZIVO BIOSCIENCE INC

NASDAQ:ZIVO (11/24/2023, 8:12:49 PM)

After market: 1.12 +0.02 (+1.82%)

1.1

-0.05 (-4.35%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners0.01%
Inst Owner Change0%
Ins Owners128.97%
Ins Owner Change0.82%
Market Cap1.91M
Revenue(TTM)10.00K
Net Income(TTM)-8.50M
Analysts82.86
Price Target36.72 (3238.18%)
Short Float %3.26%
Short Ratio1.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.84%
Min EPS beat(2)-7.84%
Max EPS beat(2)-7.84%
EPS beat(4)1
Avg EPS beat(4)-8.12%
Min EPS beat(4)-30.72%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-95.1%
Min Revenue beat(2)-95.1%
Max Revenue beat(2)-95.1%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)500%
PT rev (3m)500%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 191.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.58
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.75
OCFYN/A
SpS0.01
BVpS-0.63
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -404.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1550.36%
ROA(5y)-2266.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.62
Altman-Z -94.02
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.97%
EPS Next Y85.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.54%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.41%
OCF growth 3YN/A
OCF growth 5YN/A

ZIVO BIOSCIENCE INC / ZIVO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ZIVO BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 0 / 10 to ZIVO.


What is the valuation status of ZIVO BIOSCIENCE INC (ZIVO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZIVO BIOSCIENCE INC (ZIVO). This can be considered as Overvalued.


Can you provide the profitability details for ZIVO BIOSCIENCE INC?

ZIVO BIOSCIENCE INC (ZIVO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ZIVO BIOSCIENCE INC?

The Earnings per Share (EPS) of ZIVO BIOSCIENCE INC (ZIVO) is expected to grow by 85.38% in the next year.